Current status and future development of anti-HIV chimeric antigen receptor T-cell therapy.
Yunyu MaoChen ZhaoPeiyong ZhengXiaoyan ZhangJianqing XuPublished in: Immunotherapy (2020)
Despite the success of antiretroviral therapy in suppressing HIV to an undetectable level in the blood and improving patients' quality of life, HIV persists in antiretroviral therapy-treated patients and threatens their lives. Anti-HIV chimeric antigen receptor (CAR) T cells could offer a cure by recognizing and killing virus-producing cells in an Env-specific manner. In this review, the authors summarize several important aspects of the development of anti-HIV CAR T cells, with a special focus on the evolution of CAR design for enhanced potency and targeting specificity, and also outline the challenges that still need to be addressed to take anti-HIV CAR T cells from a hopeful approach to a real HIV cure.
Keyphrases
- antiretroviral therapy
- hiv infected
- hiv positive
- human immunodeficiency virus
- hiv aids
- hiv infected patients
- hiv testing
- hepatitis c virus
- men who have sex with men
- end stage renal disease
- newly diagnosed
- prognostic factors
- ejection fraction
- chronic kidney disease
- stem cells
- drug delivery
- cancer therapy
- cell therapy
- pi k akt
- mesenchymal stem cells